Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Truncated glp-1 derivaties and their therapeutical use

a technology of truncated glucagon and derivate, which is applied in the field of new truncated glucagonlike peptide1 (glp1) analogues, can solve the problems that the fear of injection may become a serious obstacle to the widespread use of clinically very promising compounds

Inactive Publication Date: 2010-11-18
NOVO NORDISK AS
View PDF7 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the type 2 diabetes segment most patients are treated with oral hypoglycaemic agents, and since GLP-1 compounds are expected to be an injectable pharmaceutical product these patients will be administered, the fear of injections may become a serious obstacle for the widespread use of the clinically very promising compounds.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Truncated glp-1 derivaties and their therapeutical use
  • Truncated glp-1 derivaties and their therapeutical use
  • Truncated glp-1 derivaties and their therapeutical use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[Glu22,Arg26]GLP-1(7-33)amide

[0782]

H—H A E G T F T S D V S S Y L E E Q A A R E F I A W L V—NH2

[0783]Preparation method: B

[0784]The peptide was eluted at 64% acetonitrile.

[0785]Structure confirmed by MALDI-MS

[0786]Calculated MW=3056.4

example 2

N epsilon20 {2-(2-{2-[2-(2-{2-[4-Carboxy-4-(17-carboxy-heptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl}-(Aib8,Lys20,Glu22,Val25,Arg26,Leu27,Glu30,Lys33)GLP-1(7-33)amide

[0787]

[0788]Preparation method: Method C except that the peptide was prepared on an Apex396 from Advanced Chemtech using a molar excess of 8-10 fold amino acid, DIC and HOAt / HOBt (1:1) and the Mtt group was deprotected with hexaflouroisopropanol. The final product was characterized by analytical HPLC and MALDI-MS.

[0789]HPLC (METHOD 02_B6—1):

[0790]RT=32 min

[0791]MALDI-MS=3901

[0792]Calculated MW=3900.5

example 3

N epsilon20 {2-(2-{2-[2-(2-{2-[4-Carboxy-4-(17-carboxy-heptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl}-(Aib8,Lys20,Glu22,Arg26,Glu30)GLP-1(7-33)amide

[0793]

[0794]Preparation method: Method C except that the peptide was prepared on an Apex396 from Advanced Chemtech using a molar excess of 8-10 fold amino acid, DIC and HOAt / HOBt (1:1) and the Mtt group was deprotected with hexaflouroisopropanol. The final product was characterized by analytical HPLC and MALDI-MS.

[0795]HPLC (METHOD 02_B6—1):

[0796]RT=32.9 min

[0797]MALDI-MS=3858.7

[0798]Calculated MW=3859.3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Lengthaaaaaaaaaa
Affinityaaaaaaaaaa
Login to View More

Abstract

The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.

Description

FIELD OF THE INVENTION[0001]This invention relates to the field of therapeutic peptides, i.e. to new truncated Glucagon-Like Peptide-1 (GLP-1) analogues and derivatives thereof.BACKGROUND OF THE INVENTION[0002]A range of different approaches have been used for modifying the structure of glucagon-like peptide 1 (GLP-1) compounds in order to provide a longer duration of action in vivo.[0003]WO 2006 / 097538, WO 2006 / 097536, WO 2006 / 037810, WO2006005667, WO 2005 / 027978. WO 98 / 08871 and US 2001 / 0011071 describes various GLP-1 analogues and derivatives thereof.[0004]Runge et al (Journal of Biological Chemistry, vol. 283, no. 17, pp. 11340-11347), which was published after the priority dates of the present invention, discloses the crystal structure of the extracellular domain of the ligand-bound GLP-1 receptor.[0005]Many diabetes patients particularly in the type 2 diabetes segment are subject to so-called “needle-phobia”, i.e. a substantial fear of injecting themselves. In the type 2 diabe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/605A61K38/26A61P3/10A61P3/00A61P3/06A61P3/08A61P9/10A61P9/00
CPCC07K14/605A61K38/00A61P1/00A61P1/04A61P1/14A61P3/00A61P3/04A61P3/06A61P3/08A61P3/10A61P9/00A61P9/10A61P9/12A61P25/28
Inventor SPETZLER, JANESCHAFFER, LAUGELAU, JESPERKODRA, JANOS TIBORMADSEN, KJELDGARIBAY, PATRICK WILLIAMKOFOED, JACOBREEDTZ-RUNGE, STEFFENTHOGERSEN, HENNINGPETTERSSON, IGRID
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com